Showing results (131-140 of 232) with videos related to

Sort By:
Pageof 24
The New England Journal of Medicine|May 5, 2016
Ozanimod Induction and Maintenance Treatment for Ulcerative ColitisWilliam J Sandborn, Brian G Feagan, Douglas C Wolf, et al.
Inflammatory Bowel Diseases|May 4, 2006
DLG5 R30Q is not associated with IBD in Hungarian IBD patients but predicts clinical response to steroids in Crohn's diseasePeter Laszlo Lakatos, Simon Fischer, Karolien Claes, et al.
The American Journal of Gastroenterology|August 3, 2016
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn's DiseaseStephan R Targan, Brian Feagan, Severine Vermeire, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 22, 2011
Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's diseaseMatthias Jürgens, Jestinah M Mahachie John, Isabelle Cleynen, et al.
Journal of Crohn'S & Colitis|November 12, 2023
The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b StudyBram Verstockt, Severine Vermeire, Laurent Peyrin-Biroulet, et al.
Journal of Crohn'S & Colitis|June 20, 2018
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 StudyBruce E Sands, William J Sandborn, Brian G Feagan, et al.
Gut|September 2, 2018
Population-level analysis of <i>Blastocystis</i> subtype prevalence and variation in the human gut microbiotaRaul Y Tito, Samuel Chaffron, Clara Caenepeel, et al.
Inflammatory Bowel Diseases|May 3, 2008
Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's diseaseJohn P Burke, Marc Ferrante, Karen Dejaegher, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 21, 2009
Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitisAxel U Dignass, Bernd Bokemeyer, Henning Adamek, et al.
The American Journal of Gastroenterology|July 26, 2006
Does pregnancy change the disease course? A study in a European cohort of patients with inflammatory bowel diseaseLene Riis, Ida Vind, Patrizia Politi, et al.
Pageof 24